These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23506252)

  • 1. Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis.
    Wen W; Lynch SY; Munera C; Swanton R; Ripa SR; Maibach H
    Expert Opin Drug Saf; 2013 May; 12(3):309-19. PubMed ID: 23506252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
    Steiner D; Munera C; Hale M; Ripa S; Landau C
    J Pain; 2011 Nov; 12(11):1163-73. PubMed ID: 21807566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of buprenorphine transdermal system in the management of pain in older adults.
    Pergolizzi JV; Raffa RB; Marcum Z; Colucci S; Ripa SR
    Postgrad Med; 2017 Jan; 129(1):92-101. PubMed ID: 27929709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
    Miller K; Yarlas A; Wen W; Dain B; Lynch SY; Brennan MJ; Ripa SR
    Expert Opin Pharmacother; 2013 Feb; 14(3):269-77. PubMed ID: 23374027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.
    Yarlas A; Miller K; Wen W; Lynch SY; Munera C; Pergolizzi JV; Raffa R; Ripa SR
    Postgrad Med; 2015 Jan; 127(1):38-45. PubMed ID: 25526229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.
    Ripa SR; McCarberg BH; Munera C; Wen W; Landau CJ
    Expert Opin Pharmacother; 2012 Jun; 13(9):1229-41. PubMed ID: 22409388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain.
    Yarlas A; Miller K; Wen W; Dain B; Lynch SY; Pergolizzi JV; Raffa RB; Ripa SR
    J Pain; 2013 Jan; 14(1):14-23. PubMed ID: 23200931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.
    Kapil RP; Cipriano A; Friedman K; Michels G; Shet MS; Colucci SV; Apseloff G; Kitzmiller J; Harris SC
    J Pain Symptom Manage; 2013 Jul; 46(1):65-75. PubMed ID: 23026548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec) in post-traumatic pain.
    Correa-Illanes G; Roa RG; B Piñeros JL; Ferrer FT; Adriasola VR
    Pain Manag; 2014 May; 4(3):181-90. PubMed ID: 24835268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application Site Reactions from the Buprenorphine Transdermal Patch: A Case Series.
    Meyer-Junco L; Rea B; Mendoza K; Fudin J
    J Pain Palliat Care Pharmacother; 2022 Mar; 36(1):49-54. PubMed ID: 35332848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Transdermal Buprenorphine Versus Sustained-release Tramadol in Patients With Moderate to Severe Musculoskeletal Pain: An 8-Week, Randomized, Double-Blind, Double-Dummy, Multicenter, Active-controlled, Noninferiority Study.
    Leng X; Li Z; Lv H; Zheng Y; Liu Y; Dai K; Yao C; Yan X; Zeng X
    Clin J Pain; 2015 Jul; 31(7):612-20. PubMed ID: 25503600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
    Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G
    Curr Med Res Opin; 2014 Aug; 30(8):1579-87. PubMed ID: 24689806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allergic contact dermatitis from transdermal buprenorphine.
    Vander Hulst K; Parera Amer E; Jacobs C; Dewulf V; Baeck M; Pujol Vallverdú RM; Giménez-Arnau A; Tennstedt D; Goossens A
    Contact Dermatitis; 2008 Dec; 59(6):366-9. PubMed ID: 19076888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.